NCT07514962 Minimally Invasive Coronary Artery Bypass Supported by Cangrelor
| NCT ID | NCT07514962 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cardiocentro Ticino |
| Condition | Coronary Artery Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-05-12 |
| Primary Completion | 2028-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2024-05-12 with a primary completion date of 2028-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to find out whether it is safe and practical to perform MIDCAB surgery (a minimally invasive heart bypass procedure) while patients receive a continuous cangrelor infusion during the operation. Cangrelor is a medicine that helps prevent blood clots and works quickly through a vein drip. The study compares patients receiving cangrelor during surgery to patients who had the same surgery in the past while on aspirin, with or without cangrelor given beforehand. Study Question: Can MIDCAB surgery be safely performed under cangrelor infusion, without increasing the risk of bleeding or other complications? Hypothesis: Using cangrelor during MIDCAB surgery is safe and feasible, and it provides effective protection against blood clots during the procedure. This study will help doctors understand whether intraoperative cangrelor can improve patient safety and outcomes in minimally invasive heart surgery.
Eligibility Criteria
Inclusion Criteria for the historical control arm: * Age ≥18 years old * CABG with IMA-LAD graft in MIDCAB technique Inclusion criteria for the prospective arm: * Age ≥18 years old * CABG with IMA-LAD graft in MIDCAB technique * Signed informed consent Exclusion criteria for the historical control arm * Administration of fibrinolytics or GP IIb/IIIa inhibitors * Previous intracranial hemorrhage * Known bleeding diathesis * Patients undergoing concomitant PCI and MIDCAB * Severe renal or liver disease * Pregnancy or breast feeding Exclusion criteria for the prospective arm * Unconsciousness * Known hypersensitivity to study drug (cangrelor) * Recent administration of fibrinolytics or GP IIb/IIIa inhibitors * Previous intracranial hemorrhage * Known bleeding diathesis * Patients undergoing concomitant PCI and MIDCAB * Severe renal or liver disease * Pregnancy or breast feeding
Contact & Investigator
Marco Valgimigli, Prof. Dr. Med.
PRINCIPAL INVESTIGATOR
Cardiocentro Ticino
Frequently Asked Questions
Who can join the NCT07514962 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07514962 currently recruiting?
Yes, NCT07514962 is actively recruiting participants. Contact the research team at marco.valgimigli@eoc.ch for enrollment information.
Where is the NCT07514962 trial being conducted?
This trial is being conducted at Lugano, Switzerland.
Who is sponsoring the NCT07514962 clinical trial?
NCT07514962 is sponsored by Cardiocentro Ticino. The principal investigator is Marco Valgimigli, Prof. Dr. Med. at Cardiocentro Ticino. The trial plans to enroll 30 participants.